We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Ashutosh Tewari

Ashutosh Tewari MD

Chairman of Urology, Department of Urology, Icahn School of Medicine, Mount Sinai Hospital, New York, New York

Dr. Tewari is the Chairman of Urology at Ichan School of Medicine/Mount Sinai Hospital System.

He studies various aspects of prostate cancer, including genomics, biobanking, imaging, surgical prostate anatomy, genetic risk profiling, epidemiology, racial disparities, risk modeling and survivorship issues. To further his commitment to better surgical outcomes, Dr. Tewari has worked on improving the accuracy of staging efforts, focusing on novel imaging approaches and developing predictive modeling tools. He has performed over 5,000 robotic prostatectomies and has established a prostate biorepository at the Prostate Cancer Institute in New York.

Dr. Tewari has been involved with genetic studies evaluating risk for aggressive prostate cancer and has coauthored several papers addressing genomic signature of prostate cancer. His current research projects focus on a) the development of new surgical techniques and modifications to examine functional and oncological improvements in prostate cancer surgery; b) the genetic hallmark of cancer and utilizing single cell sequencing to revolutionize patient diagnosis by supporting pathology with molecular facts; c) evaluating molecular differences to explain racial disparities in outcomes; d) developing novel approaches for describing radiological phenotypes of aggressive prostate cancer; e) and exploring the utility of multiparameteric MRI as the Male “Prostatogram” for optimal management of prostate cancer and monitoring active surveillance of patients. Furthermore, his research group has established a system of preoperative prostate cancer risk stratification, annotated 3 Tesla MRI imaging, intraoperative cancer localization, post-operative schematic mapping of the prostate and has redesigned prostatectomy tissue procurement from the ground up to routinely provide both formalin-fixed paraffin embedded and frozen sample sections. As a result, histopathology and molecular genetic analysis can each be done on adjacent sections without any compromise and exact tissue source could be oriented from various parts of the specimen, including cancer cells that have invaded through the capsule.